How Tyvaso Works

Direct-to-the-lungs Prostacyclin Analog

TYVASO promotes direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.1

The prolonged vasodilation demonstrated by TYVASO is thought to be linked to the stability of treprostinil and the way treprostinil may be stored and slowly released from lung tissue after inhalation.2

Make an Impact for your Patients

  • At intermediate risk* OR
  • In need of fast titration OR
  • Not appropriate for oral prostacyclin-class medication

*Risk was evaluated at baseline for the TRIUMPH population utilizing COMPERA registry methodology.3 Three noninvasive low-risk criteria were assessed: 6MWD >440m, FC I/II, and NT-proBNP <300 ng/L. Patients with available data for all three parameters at baseline were included in the analysis (n=196; 83%). The majority of patients in the analysis (97%) were classified as intermediate risk at baseline.4

In the pivotal trial, the average time to target dose was 3 weeks.5

Hero ImageHero Image

*Risk was evaluated at baseline for the TRIUMPH population utilizing COMPERA registry methodology.3 Three noninvasive low-risk criteria were assessed: 6MWD >440m, FC I/II, and NT-proBNP <300 ng/L. Patients with available data for all three parameters at baseline were included in the analysis (n=196; 83%). The majority of patients in the analysis (97%) were classified as intermediate risk at baseline.4

In the pivotal trial, the average time to target dose was 3 weeks.5